These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1096 related items for PubMed ID: 32581055

  • 1. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
    Zhang W, Liu Y, Yan Z, Yang H, Sun W, Yao Y, Chen Y, Jiang R.
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
    [Abstract] [Full Text] [Related]

  • 2. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP, Ning WR, Jiang ZZ, Peng ZP, Zhu LY, Zhuang SM, Kuang DM, Zheng L, Wu Y.
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.
    Wu Q, Zhou W, Yin S, Zhou Y, Chen T, Qian J, Su R, Hong L, Lu H, Zhang F, Xie H, Zhou L, Zheng S.
    Hepatology; 2019 Jul; 70(1):198-214. PubMed ID: 30810243
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF, Liu H, Gao R, Zhou M, Ma J, Zhang Y, Zhao J, Chen Y, Zhang T, Huang F, Pan N, Zhang J, Fox BA, Hu HM, Wang LX.
    J Immunother Cancer; 2018 Dec 18; 6(1):151. PubMed ID: 30563569
    [Abstract] [Full Text] [Related]

  • 7. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J, Zhang N, Sun H, Su L, Zhang C, Xu H, Feng J, Wang M, Chen J, Liu L, Shan J, Shen J, Yang Z, Wang G, Zhou H, Prieto J, Ávila MA, Liu C, Qian C.
    Gastroenterology; 2020 Feb 18; 158(3):664-678.e24. PubMed ID: 31678303
    [Abstract] [Full Text] [Related]

  • 8. Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages.
    Jiang C, Yuan F, Wang J, Wu L.
    Immunobiology; 2017 Apr 18; 222(4):651-657. PubMed ID: 28017495
    [Abstract] [Full Text] [Related]

  • 9. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
    Park DJ, Sung PS, Lee GW, Cho S, Kim SM, Kang BY, Hur W, Yang H, Lee SK, Lee SH, Jung ES, Seo CH, Ahn J, Choi HJ, You YK, Jang JW, Bae SH, Choi JY, Yoon SK.
    Int J Mol Sci; 2021 Apr 29; 22(9):. PubMed ID: 33946835
    [Abstract] [Full Text] [Related]

  • 10. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity.
    Tao Z, Ruan H, Sun L, Kuang D, Song Y, Wang Q, Wang T, Hao Y, Chen K.
    Cancer Immunol Res; 2019 Jul 29; 7(7):1135-1147. PubMed ID: 31113805
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Endoplasmic Reticulum Stress Causes Liver Cancer Cells to Release Exosomal miR-23a-3p and Up-regulate Programmed Death Ligand 1 Expression in Macrophages.
    Liu J, Fan L, Yu H, Zhang J, He Y, Feng D, Wang F, Li X, Liu Q, Li Y, Guo Z, Gao B, Wei W, Wang H, Sun G.
    Hepatology; 2019 Jul 29; 70(1):241-258. PubMed ID: 30854665
    [Abstract] [Full Text] [Related]

  • 13. C-X-C chemokine receptor 2 (Cxcr2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1 (PD-L1).
    Wan Y, Ge K, Zhou W, Lu J, Jia C, Zhu H.
    Biol Chem; 2021 May 26; 402(6):729-737. PubMed ID: 33583159
    [Abstract] [Full Text] [Related]

  • 14. PD-L1+NEUT, Foxp3+Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma.
    Zhou L, Wang J, Lyu SC, Pan LC, Shi XJ, Du GS, He Q.
    Technol Cancer Res Treat; 2021 May 26; 20():15330338211045820. PubMed ID: 34605709
    [Abstract] [Full Text] [Related]

  • 15. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
    Liu H, Shen J, Lu K.
    Biochem Biophys Res Commun; 2017 Apr 29; 486(2):239-244. PubMed ID: 28254435
    [Abstract] [Full Text] [Related]

  • 16. KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D.
    Wang Y, Cao K.
    J Immunol Res; 2021 Apr 29; 2021():9965099. PubMed ID: 34307695
    [Abstract] [Full Text] [Related]

  • 17. Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis.
    Yasuoka H, Asai A, Ohama H, Tsuchimoto Y, Fukunishi S, Higuchi K.
    Sci Rep; 2020 Jun 25; 10(1):10377. PubMed ID: 32587357
    [Abstract] [Full Text] [Related]

  • 18. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, Mancham S, Pedroza-Gonzalez A, Polak WG, de Jonge J, Gaspersz M, Dong H, Thielemans K, Pan Q, IJzermans JNM, Bruno MJ, Kwekkeboom J.
    Gastroenterology; 2017 Oct 25; 153(4):1107-1119.e10. PubMed ID: 28648905
    [Abstract] [Full Text] [Related]

  • 19. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells.
    Wan S, Zhao E, Kryczek I, Vatan L, Sadovskaya A, Ludema G, Simeone DM, Zou W, Welling TH.
    Gastroenterology; 2014 Dec 25; 147(6):1393-404. PubMed ID: 25181692
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.